- Home
- VRCA vs UG Comparison
VRCA vs UG Comparison
Compare VRCA & UG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRCA
- UG
- Stock Information
- Founded
- VRCA 2013
- UG 1942
- Country
- VRCA United States
- UG United States
- Employees
- VRCA N/A
- UG N/A
- Industry
- VRCA Biotechnology: Pharmaceutical Preparations
- UG Package Goods/Cosmetics
- Sector
- VRCA Health Care
- UG Consumer Discretionary
- Exchange
- VRCA Nasdaq
- UG Nasdaq
- Market Cap
- VRCA 40.6M
- UG 36.4M
- IPO Year
- VRCA 2018
- UG N/A
- Fundamental
- Price
- VRCA $3.96
- UG $7.61
- Analyst Decision
- VRCA Buy
- UG
- Analyst Count
- VRCA 4
- UG 0
- Target Price
- VRCA $60.00
- UG N/A
- AVG Volume (30 Days)
- VRCA 348.8K
- UG 7.3K
- Earning Date
- VRCA 11-06-2025
- UG 11-07-2025
- Dividend Yield
- VRCA N/A
- UG 9.25%
- EPS Growth
- VRCA N/A
- UG N/A
- EPS
- VRCA N/A
- UG 0.56
- Revenue
- VRCA $14,704,000.00
- UG $10,856,174.00
- Revenue This Year
- VRCA $332.45
- UG N/A
- Revenue Next Year
- VRCA $12.85
- UG N/A
- P/E Ratio
- VRCA N/A
- UG $13.57
- Revenue Growth
- VRCA 5.72
- UG N/A
- 52 Week Low
- VRCA $3.82
- UG $7.25
- 52 Week High
- VRCA $17.38
- UG $14.35
- Technical
- Relative Strength Index (RSI)
- VRCA 39.62
- UG 46.18
- Support Level
- VRCA $3.93
- UG $7.36
- Resistance Level
- VRCA $4.54
- UG $7.70
- Average True Range (ATR)
- VRCA 0.32
- UG 0.16
- MACD
- VRCA 0.01
- UG 0.02
- Stochastic Oscillator
- VRCA 11.00
- UG 34.25
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About UG United-Guardian Inc.
United-Guardian Inc manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. Its product portfolio includes Klensoft, Deselex, Renacidin, Lubrajel Fluid. The company's pharmaceutical products are sold to and distributed by full-line drug wholesalers throughout the United States. Its medical and specialty industrial products are sold directly by the company to the end-users of those products or, in some cases, to contract manufacturers used by some of those end users. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. It derives key revenue from the sales made in the U.S.